A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition

Cancer Discovery

Volumn 4, Issue 1, 2014, Pages 69-79

  Shi, Hubing ^a,b   Hong, Aayoung ^a,b   Kong, Xiangju ^a,b   Koya, Richard C ^a,b   Song, Chunying ^a,b   Moriceau, Gatien ^a,b   Hugo, Willy ^a,b   Yu, Clarissa C ^a,b   Ng, Charles ^a,b   Chodon, Thinle ^a,b   Scolyer, Richard A ^c,d,f   Kefford, Richard F ^c,e,f   Ribas, Antoni ^a,b   Long, Georgina V ^c,e,f   Lo, Roger S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 8 [4 (1 AMINOCYCLOBUTYL) PHENYL] 9 PHENYL 1, 2, 4 TRIAZOLO [3, 4 F] [1, 6] NAPHTHYRIDIN 3 (2H) ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; BUPARLISIB; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GSK 2141795; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE; PLATELET DERIVED GROWTH FACTOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; SELUMETINIB; SUNITINIB; TRAMETINIB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VEMURAFENIB;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR BIOPSY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HEK293 CELLS; HUMANS; MELANOMA; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SKIN NEOPLASMS;

EID: 84891893623     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0279     Document Type: Article

References (23)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-954.
2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
3. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber J S, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-714.
4. Lo RS. Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas. Pharmacogenomics 2012;13:125-128.
5. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-977.
6. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480:387-390.
7. Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, et al. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov 2012; 2: 414-424.
8. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012; 3: 724.
9. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014;4:80-93.
10. Duncan JS, Whittle MC, Nakamura K, Abelll AN, Midland AA, Zawistowski JS, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012;149:307-321.
11. Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012;22:668-682.
12. Shi H, Kong X, Ribas A, Lo RS. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to B-RAF(V600E) inhibition. Cancer Res 2011;71:5067-5074.
13. Lo RS. Receptor tyrosine kinases in cancer escape from BRAF inhibitors. Cell Res 2012;22:945-947.
14. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-444.
15. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009;16:21-32.
16. Flaherty K T, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-1703.
17. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013;494:251-255.
18. Lo RS, Ribas A, Long GV, Ballotti R, Berger M, Hugo W, et al. Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, California. Pigment Cell Melanoma Res 2013;26:1-7.
19. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012;150: 251-263.
20. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012;44:1006-1014.
21. Shull AY, Latham-Schwark A, Ramasamy P, Leskoske K, Oroian D, Birtwistle MR, et al. Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS ONE 2012;7:43369.
22. Catalanotti F, Solit DB, Pulitzer MP, Berger MF, Scott SN, Iyriboz T, et al. Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res 2013;19:2257-2264.
23. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013;31:1767-1774.